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Human NOD2 Recognizes Structurally Unique Muramyl Dipeptides
from Mycobacterium leprae
Mirjam Schenk,a* Sebabrata Mahapatra,c Phuonganh Le,a Hee Jin Kim,c Aaron W. Choi,a Patrick J. Brennan,c John T. Belisle,c
Robert L. Modlina,b
Division of Dermatology, Department of Medicine,a and Department of Microbiology, Immunology and Molecular Genetics,b David Geffen School of Medicine at
University of California, Los Angeles, California, USA; Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State
University, Fort Collins, Colorado, USAc
The innate immune system recognizes microbial pathogens via pattern recognition receptors. One such receptor, NOD2, via
recognition of muramyl dipeptide (MDP), triggers a distinct network of innate immune responses, including the production of
interleukin-32 (IL-32), which leads to the differentiation of monocytes into dendritic cells (DC). NOD2 has been implicated in
the pathogenesis of human leprosy, yet it is not clear whetherMycobacterium leprae, which has a distinct MDP structure, can
activate this pathway. We investigated the effect of MDP structure on the innate immune response, finding that infection of
monocytes withM. leprae induces IL-32 and DC differentiation in a NOD2-dependent manner. The presence of the proximal
L-Ala instead of Gly in the common configuration of the peptide side chain ofM. leprae did not affect recognition by NOD2 or
cytokine production. Furthermore, amidation of the D-Glu residue did not alter NOD2 activation. These data provide experi-
mental evidence that NOD2 recognizes naturally occurring structural variants of MDP.
The ability of the innate immune response to defend againstmicrobial invaders involves germ line-encoded pattern rec-
ognition receptors (PRRs) which detect highly conserved
pathogen-associated molecular patterns (PAMPs) of infectious
agents. One such PRR, nucleotide-binding oligomerization do-
main 2 (NOD2), is a cytoplasmic receptor belonging to the
NOD-like receptor family. NOD2 recognizes muramyl dipep-
tide (MDP), part of the peptidoglycan (PG) cell walls of Gram-
positive and Gram-negative bacteria (1, 2).
We previously found that activation of NOD2, but not Toll-
like receptor 2/1 (TLR2/1) or NOD1, induced the production of
interleukin-32 (IL-32) in human monocytes. In addition, NOD2
activation induced the IL-32-dependent differentiation of mono-
cytes into dendritic cells (DC). These IL-32-derived DC were dis-
tinguished from granulocyte-macrophage colony-stimulating
factor (GM-CSF)-differentiated DC in having the capacity to
cross-present exogenous antigen via major histocompatibility
complex (MHC) class I to CD8 T cells (3). Cross-presentation
facilitates the induction of CD8 cytotoxic T cell responses against
intracellular pathogens that reside in the endosomal pathway. The
biological relevance of this pathway was demonstrated in leprosy,
in which NOD2, IL-32, and CD1 DC all were more highly ex-
pressed in skin lesions from patients with the self-limited tuber-
culoid (T-lep) form versus the progressive lepromatous leprosy
(L-lep) form. The relevance of NOD2 in the pathogenesis of lep-
rosy is further suggested by the association of NOD2 gene poly-
morphisms with susceptibility to leprosy (4, 5).
MDP is the minimal essential structure of bacterial peptidogly-
can required for its immunological effects, including the activity
of Freund’s complete adjuvant, which contains mycobacterial cell
walls (6, 7). Typically, immunologic studies of NOD2 activation
are performed using a synthetic MDP analogue, characterized by
N-acetylmuramyl-L-alanyl-D-isoglutamine (8), which is present
in most bacteria. The MDP in Mycobacterium spp. has several
structurally distinct features, based on studies with the readily
cultivable M. smegmatis and M. tuberculosis. MDP in these myco-
bacteria contains muramic acid residues that areN-glycolylated as
well as N-acetylated (9, 10). The carboxyl functions of the peptide
side chains are also partially modified by amidation, methylation,
or an additional Gly residue (11, 12).
MDP from in vivo-derived and noncultivable M. leprae pos-
sesses the basic structural features of MDP from other mycobac-
teria but with the replacement of the proximal L-alanine by glycine
in the peptide side chain and the lack of N-glycolylated muramic
acid residues (10, 13). Therefore, the M. leprae peptidoglycan-
derived MDP is structurally unique compared to other mycobac-
teria, as well as other pathogenic bacteria, yet its ability to activate
the innate immune response is unknown. Given that structural
modifications of MDP can alter biological activity (8, 14–17), we
investigated the relationship of the structure of theM. lepraeMDP
with its ability to trigger immune activation of human monocytes.
MATERIALS AND METHODS
Bacteria and microbial ligands. For activation of monocytes and HEK-
NOD2 reporter cells, we used MDP (1 g/ml; Invivogen, San Diego, CA),
LL-MDP (1g/ml; Invivogen, San Diego, CA), liveM. leprae (multiplicity of
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infection [MOI] of 10), and sonicated M. leprae (10 g/ml). M. leprae was
obtained from the footpad of nu/nu mice as described previously (18) and
was provided by James L. Krahenbuhl of the National Hansen’s Disease Pro-
grams, Health Resources Service Administration, Baton Rouge, LA. The M.
leprae fractions (M. leprae sonicate, mAGP, and peptidoglycan) were ob-
tained from armadillo spleen-derived M. leprae and generated as described
elsewhere (13, 19, 20). All reagents were tested for endotoxin by LAL assay
(Limulus amebocyte lysate; detection limit, 0.1 EU/ml; Lonza, Anaheim,
CA).
Preparation and analysis of soluble muropeptide from M. leprae
PG. Peptidoglycan was isolated, solubilized, and fractionated by size ex-
clusion chromatography on a Superdex peptide 10/300 GL column (Am-
ersham Biosciences, Pittsburgh, PA) using the conditions described by
Mahapatra et al. (10). The muropeptide-containing fractions were ana-
lyzed by liquid chromatography-mass spectrometry (LC-MS) using an
Agilent 1200 series high-performance liquid chromatography (HPLC)
system connected to a 6520 series accurate time-of-flight mass spectrom-
eter (Q-TOF) by following conditions previously described (21). The pos-
itive ion-MS data were processed with Agilent MassHunter qualitative
analysis software to identify potential compounds ions, followed by a
search against a custom database containing calculated monoisotopic ion
masses of possible uncross-linked and cross-linked muropeptides from
M. leprae PG with a maximum molecular mass of 2 kDa to predict the struc-
ture of the compound ions. The amino acid compositions of the muropeptide
fractionated by size exclusion chromatography were also analyzed by an EZ:
faast GC-MS kit by following the manufacturer’s instructions (Phenomenex,
Torrance, CA). The concentrations of the muropeptides were normalized
based on the abundance of diaminopimelic acid residues.
Enzymatic synthesis of M. leprae MDP analogues. UDP-N-acetyl-
muramic acid (UDP-MurNAc) was synthesized by following methods
described previously (22). UDP-N-acetylmuramyl-glycinyl–D-glutamate
was synthesized from UDP-MurNac, Gly, and D-Glu using recombinant
MurC and MurD enzymes of Escherichia coli. The reaction buffer and
conditions used have been described previously (23, 24). UDP-N-acetyl-
muramyl-glycinyl-D-isoglutamine was synthesized in a similar reaction,
except D-Glu was replaced with D-isoglutamine. The reaction mixtures
were deproteinated and the nucleotide-linked MDPs were purified by
ion-exchange chromatography by following the methods described pre-
viously (23). Nucleotides were removed by hydrolysis in 0.2 M trifluoro-
acetic acid at 60°C for 1 h, and the resulting MurNAC-glycinyl–D-gluta-
mate or MurNAC-glycinyl-D–isoglutamine was dried under a stream of
N2, resuspended in water, purified by size exclusion chromatography, and
then analyzed by LC-MS as described above. The amino acid composi-
tions of MDPs were analyzed by GC-MS as described above.
Monocyte purification. We obtained whole blood from healthy do-
nors (UCLA I.R.B. 11-001274) with informed consent. Peripheral blood
mononuclear cells (PBMCs) were isolated using Ficoll (GE Healthcare,
Pittsburgh, PA) gradient centrifugation, and monocytes were further en-
riched using a Percoll density gradient (GE Healthcare, Pittsburgh, PA) and
subsequent adherence in 1% fetal calf serum (FCS) for 2 h or were purified
using an EasySep human monocyte enrichment kit without CD16 depletion
(Stemcell Technologies, Vancouver, Canada). Monocyte purity was found to
be80% as measured by CD14 expression. Cells were cultured for 24 h in
RPMI with 10% FCS (Omega Scientific, Tarzana, CA), penicillin (50 U/ml),
streptomycin (50g/ml), and sodium pyruvate (1 mM).
Flow cytometry. Cell surface expression of antigenic determinants
was measured using epitope-specific antibodies, and cells were acquired
and analyzed as described previously (25). For detection of CD1b, a
monoclonal primary antibody (Bcd3.1; ATCC, Manassas, VA) was used,
followed by an IgG1-specific secondary antibody (Invitrogen, Carlsbad,
CA). Samples were acquired on an LSR II machine (BD, San Jose, CA) and
analyzed using FlowJo software.
Cytokine ELISAs. Secreted IL-32 protein in the supernatant was mea-
sured using an IL-32 sandwich enzyme-linked immunosorbent assay
(ELISA) kit (SEL101; YbdY Biotech, South Korea) or a matched antibody
pair (BioLegend, San Diego, CA). To measure secreted IL-1, IL-6, and
tumor necrosis factor alpha (TNF-), matched antibody pairs were used
according to the manufacturer’s recommendations (Biosource, San Di-
ego, CA). For detection we used streptavidin-horseradish peroxidase
(HRP) (1:1,000; Pierce, Rockford, IL) and ABTS [2,2=-azinobis(3-ethylben-
zthiazolinesulfonic acid)] HRP substrate mixture (Kirkegaard and Perry Lab-
oratories, Inc., Gaithersburg, MD), and plates were read at 405 nm.
Real-time qPCR. Following stimulation of monocytes, RNA was iso-
lated using TRIzol (Invitrogen, Carlsbad, CA), cDNA and quantitative
PCR (qPCR) was performed as previously described (26). QuantiTect
primers (Qiagen, Hilden, Germany) were used. The relative quantities of
the gene tested per sample were calculated against h36B4 using the delta
cycle threshold formula as previously described (27). The data were nor-
malized by fold change to medium control samples.
HEK NOD2 reporter assay. HEK-Blue hNOD2 reporter cells (Invivo-
gen, San Diego, CA) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM), 4.5 g/liter glucose, 10% FCS (Omega Scientific, Tarzana, CA) with
FIG 1 NOD2L is a potent inducer of IL-32 and DC differentiation. siRNA
knockdown of NOD2 in purified human monocytes significantly reduced
NOD2 expression, shown as arbitrary units (AU) (A), blocked syn-MDP and
live M. leprae induction of IL-32 mRNA, shown as mean fold change (FC) (B),
and reduced the induction of CD1b DC, shown as the percentage of positive
cells (C). Data are represented as means standard errors of the means (SEM)
(n 	 4). Statistical significance was calculated by two-tailed Student’s t test.
Asterisks indicate statistically significant differences: *, P 0.05; **, P 0.01.
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50 U/ml penicillin, 50 g/ml streptomycin, and 100 g/ml normocin. For
antibiotic selection, 30 g/ml blasticidin and 100 g/ml zeocin were added.
HEK-Blue detection was achieved by adding 2.5
104 cells to a 20-l sample,
which was incubated at 37°C in 5% CO2 for 16 h. Secreted embryonic alkaline
phosphatase (SEAP) was quantified using HEK-Blue detection (Invivogen,
San Diego, CA) and measured by a spectrophotometer at 655 nm.
RESULTS
M. leprae infection of human monocytes induces IL-32 via
NOD2. Although NOD2 single-nucleotide polymorphisms and
NOD2 downstream immune responses are thought to contribute
to the pathogenesis of leprosy, it is not clear whether M. leprae,
which has a distinct MDP structure, activates the NOD2 pathway. To
determine the role of NOD2 in leprosy infection, we silenced NOD2
gene expression in human monocytes using short interfering RNAs
(siRNAs) (Fig. 1A) and measured the induction of IL-32 mRNA in
response to infection with live M. leprae. IL-32 induction was mea-
sured, since it is specific to NOD2 versus TLR2/1 activation and is
required to induce CD1b DC differentiation and cross-presenta-
tion, and its expression at the site of disease correlates with the self-
limited versus progressive form of leprosy. Knockdown of NOD2
(siNOD2) almost completely blocked IL-32 induction in response to
liveM. leprae compared to the control (siCtrl)-treated cells (Fig. 1B).
Similarly, knockdown of NOD2 blocked the response to the synthetic
conventional MDP (N-acetylmuramyl-L-alanyl-D-isoglutamine, also
called syn-MDP). At the same time, live M. leprae and syn-MDP
induced expression of CD1b in monocytes, indicative of DC differ-
entiation. Both live M. leprae and syn-MDP induced CD1b mRNA
and protein expression, which was significantly reduced in the ab-
sence of NOD2 (Fig. 1C). These data indicate that NOD2 is crucial for
the innate recognition of M. leprae in infected monocytes.
Identification of theM. leprae ligand(s) that induces IL-32. To
identify the M. leprae ligand(s) that regulates IL-32 expression, we
cultured monocytes with live or sonicated bacilli, the M. leprae my-
colyl-arabinogalactan-peptidoglycan (mAGP), the digested M. lep-
rae peptidoglycan, or enriched fractions of muropeptides derived
from M. leprae peptidoglycan. As reference controls, we compared
the mycobacterial ligands to syn-MDP and inactive synthetic MDP
(N-acetylmuramyl-L-alanyl-L-isoglutamine, or LL-syn-MDP) (Fig.
2A). The induction of IL-32 mRNA expression was significantly
greater in cells treated with either live or sonicated M. leprae, the
peptidoglycan fraction containing the muropeptides and syn-MDP,
compared to the medium control (Fig. 2A). TheM. lepraemAGP did
not induce IL-32 expression. The mAGP complex is hydrophobic
and insoluble and might not be accessible to host lytic enzymes that
would release MDP, which is required for NOD2 activation. Addi-
tionally, M. leprae subcellular fractions, including cell wall core, cell
wall protein, and cytosolic protein, which are expected to lack MDP,
also did not induce IL-32 production (data not shown). The ste-
reospecificity of NOD2 ligand recognition was confirmed in studies
with LL-MDP which failed to induce IL-32.
The muropeptide fraction (M. leprae peptidoglycan) consisted
of a heterogeneous mixture of muropeptides with potential mod-
ification sites on sugar and peptide residues. To identify the M.
leprae ligand(s) within the M. leprae peptidoglycan preparation
that was responsible for NOD2 activation, we further fractionated
the digested M. leprae peptidoglycan by size exclusion chromatog-
raphy (see Fig. S1 in the supplemental material) and tested these for
their ability to induce IL-32 expression. TheM. leprae peptidoglycan
fraction 18 (F-18) was found to be the most potent, such that F-18
and the neighboring fractions were studied in greater detail. F-18
induced a 6-fold increase in IL-32 expression compared to the me-
dium control (Fig. 2B). In comparison, F-16, F-17, and F-19 upregu-
lated IL-32 expression by about 2-fold. The syn-MDP increased ex-
pression by 3-fold compared to that with medium alone.
F-18 of theM. leprae peptidoglycan digest and the two adjacent
fractions (F-17 and F-19) were analyzed by LC-MS to determine
their composition and relative quantity of muropeptides. Muro-
peptide composition was elucidated by interrogation of the MS
data against a database of potential muropeptide structures and
their calculated masses (Table 1). A comparison of the structures
FIG 2 Induction of IL-32 by M. leprae. (A) Purified human monocytes were cultured with live M. leprae (MOI of 10) or 10 g/ml of either sonicated bacilli
(mLEP-son), digested M. leprae peptidoglycan (mLEP-PG), M. leprae mycolyl-arabinogalactan-peptidoglycan (mAGP), synthetic MDP (syn-MDP), or inactive
synthetic MDP (LL-syn-MDP), and IL-32 gene expression was measured. (B) Four enriched fractions of muropeptides derived from mLEP-PG (mLEP-PG F-16,
-17, -18, and -19) were tested for their ability to induce IL-32 expression and compared to digested M. leprae peptidoglycan (mLEP-PG) and synthetic MDP
(syn-MDP). Data are represented as mean fold change (FC) compared to the medium control (ctrl) SEM (n	 6). Statistical significance was calculated by
two-tailed Student’s t test. Asterisks indicate statistically significant differences compared to media control: *, P 0.05; **, P 0.01.
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in the variousM. leprae peptidoglycan fractions revealed that F-17
was comprised entirely of cross-linked muropeptides, while F-18
was a mixture of cross-linked and monomeric muropeptides and
F-19 contained only monomeric muropeptides (Table 1). How-
ever, M. leprae peptidoglycan F-18 possessed a greater abundance
of monomeric muropeptides in which the MurNAc residue was
not modified to an anhydro form during enzymatic hydrolysis.
Thus, this unmodified form of the monomeric muropeptide was
likely the reason for the increased IL-32 induction by F-18.
Innate immune responses toM. lepraeMDP.The structure of
M. leprae peptidoglycan-derived muramyl dipeptide is unique, as
the first amino acid residue of the tetrapeptide side chain is Gly
instead of L-Ala and the D-Glu residues are not fully amidated.
Thus, MDP naturally derived from M. leprae would contain a
mixture of amidated and nonamidated N-acetylmuramyl-glyci-
nyl-D-isoglutamine (Fig. 3A). To further test structure-function
relationships of M. leprae MDP, we enzymatically synthesized the
amidated and nonamidated form of MDP and confirmed the mo-
lecular structures by mass spectrometry (Fig. 3B; see also Fig. S1 in
the supplemental material). The [MH] molecular ion of m/z
493.2168 belonged to the syn-MDP standard. The [MH] mo-
lecular ion ofm/z 480.1861 yielded a calculated molecular formula
FIG 3 Chemical structures of synthetic MDP and M. leprae MDP. (A) Structural differences between the different MDPs are highlighted (box). The first amino
acid residue of M. leprae MDP is Gly instead of L-Ala, and the D-Glu residue is amidated [mLEP-MDP(NH2)] or nonamidated (mLEP-MDP). (B) mLEP-
MDP(NH2) and mLEP-MDP were synthesized enzymatically, and the molecular structures were confirmed by mass spectrometry: [MH]
 of 493.2168 m/z
belongs to syn-MDP, [MH] of 480.1861 m/z has a calculated molecular formula of C18H29N3O12, which is consistent with the molecular formula of
mLEP-MDP, and [MH] of 479.2002 m/z has a calculated molecular formula of C18H30N4O11, which is also the molecular formula of mLEP-MDP(NH2).
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of C18H29N3O12 that was consistent with the molecular formula of
M. leprae MDP, and the [MH] molecular ion of m/z
479.2002 represented amidated MDP of M. leprae MDP(NH2)
with a calculated molecular formula of C18H30N4O11 (Fig. 3B;
see also Fig. S1).
The cytokine induction in human monocytes was compared
for these structurally distinct MDPs. The proinflammatory cyto-
kines IL-32, IL-1, and IL-6 were all significantly induced by syn-
MDP and the amidated and nonamidatedM. lepraeMDP, as mea-
sured by mRNA expression (Fig. 4A) and protein secretion (Fig.
4B), indicating that the unique structure of the M. leprae MDP
does not interfere with its ability to activate an innate immune
response. The amidated form of the M. leprae MDP showed a
trend, albeit not significant, to induce a stronger IL-32, IL-1B, and
IL-6 mRNA response. IL-1B mRNA induction was 1.2-fold higher
in monocytes stimulated with the amidated form of the M. leprae
MDP than the nonamidated and synthetic form. However, the
level of secreted IL-1 protein was 1.6-fold higher in monocytes
cultured with the syn-MDP than the amidatedM. lepraeMDP and
2.4-fold higher than the nonamidated form of M. leprae MDP.
The discrepancy between the induction of IL-1B mRNA and pro-
tein could be a consequence of differences in inflammasome acti-
vation, which requires further investigation of caspase/inflam-
masome components. To determine whether these compounds
are comparably potent throughout a wide range of concentra-
tions, we performed a dose titration and measured IL-32 induc-
tion. The compounds induced comparable amounts of IL-32
throughout a range of concentrations, with peak induction at 1
g/ml (see Fig. S2 in the supplemental material).
M. leprae MDP activates NOD2 and induces human mono-
cytes to differentiate into DC. CD1b DC are potent antigen-
presenting cells in induction of an adaptive T cell response in
leprosy (28, 29). Here, we found that M. leprae MDP induces
human monocytes to differentiate into CD1b DC with a magni-
tude similar to that of syn-MDP (Fig. 5). The frequency of CD1b
DC at the site of disease correlates with clinical forms of the dis-
FIG 4 Cytokine response to structurally distinct MDPs. Purified human monocytes were activated by adding 1 g/ml of syn-MDP, mLEP-MDP(NH2), or
mLEP-MDP. After 24 h, IL-32, IL-1, and IL-6 induction was measured by mRNA expression as fold change (FC) compared to the medium control (A) and
protein secretion (B). Data are represented as means SEM (n 6).
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ease, i.e., greater in T-lep than in L-lep lesions (30). In addition, we
showed that gene expression of both IL-32 and CD1B were signif-
icantly greater in T-lep than L-lep lesions (3). Therefore, the abil-
ity of M. leprae MDP to induce both IL-32 and CD1b DC is
linked to host defense at the site of infection.
M. lepraeMDP is recognized via NOD2. To demonstrate that
recognition of the M. leprae MDP was mediated by NOD2, we
used a HEK NOD2 reporter cell line. This allows us to quantita-
tively assess NOD2 activation by structurally different com-
pounds over a range of concentrations. At lower concentrations
(0.01 and 0.1 g/ml), the amidated form of M. leprae MDP was
found to be a more potent activator of NOD2; however, this dif-
ference was not observed at higher concentrations (1g/ml) (Fig.
6). These data show that the M. leprae MDP is recognized by
NOD2 in transfected HEK reporter cells.
The role of NOD2 in M. leprae MDP-induced immune re-
sponses was tested by knockdown of NOD2 expression in mono-
cytes using siRNAs with the subsequent measurement of cytokine
responses. NOD2 mRNA expression was inhibited in mono-
cytes transfected with siNOD2 by about 90% compared to that
in siCtrl-transfected cells (Fig. 7A). The induction of IL-32, IL-1B,
and IL-6 mRNAs (Fig. 7B) and protein (Fig. 7B) was significantly
reduced by the knockdown of NOD2 mRNAs for all forms of
MDP tested. Together, these data indicate that M. leprae MDP,
despite its unique structure, activates human monocytes via
NOD2 to trigger a range of innate immune responses with rele-
vance to the pathogenesis of leprosy which are comparable to
those induced by the MDP structures found in most other bac-
teria.
DISCUSSION
The importance of NOD2 activation in immune responses has
become evident since the identification of MDP as a key compo-
nent of mycobacterial cell walls responsible for conferring adju-
FIG5 Induction of DC differentiation by different MDPs. Purified human monocytes were activated using syn-MDP, mLEP-MDP(NH2), and mLEP-MDP, and
DC differentiation was measured by flow cytometry for CD1b expression. A representative histogram (A) and the mean percentage of CD1b-positive cells SEM
(B) are shown (n	 5).
FIG 6 Quantification of NOD2 signaling induced by structurally distinct
MDPs. HEK-NOD2 reporter cells were used to quantitatively assess NOD2
activation by stimulating cells with structurally different MDP compounds
[syn-MDP, mLEP-MDP-(NH2), and mLEP-MDP] over a range of concentra-
tions (0.001 to 1g/ml). Data are represented as mean arbitrary units (AU)
SEM (n	 6).
NOD2 Recognizes Mycobacterium leprae Muramyl Dipeptide
September 2016 Volume 84 Number 9 iai.asm.org 2435Infection and Immunity
vant activity (6, 31) in inducing both B cell (32) and T cell (33)
responses. NOD2 recognition of MDP triggers the induction of
specific inflammatory responses to combat bacterial infection, in-
cluding the production of IL-32, which in leprosy is linked to host
defense against the pathogen M. leprae. Nevertheless, it was un-
known whether the unique structure of the M. leprae MDP acti-
vates a NOD2 response. Here, we demonstrate that infection of
monocytes with M. leprae induces the NOD2-dependent produc-
tion of IL-32 as well as DC differentiation. The M. leprae MDP,
which includes a replacement of L-Ala with Gly in the peptide side
chain with or without amidation of the D-Glu residue, triggered
IL-32 production and DC differentiation. These data provide ev-
FIG 7 siNOD2 abolished MDP-induced cytokine response. (A) Purified human monocytes were transfected with siNOD2 or siCtrl, and NOD2 gene expression
was measured and is shown in arbitrary units (AU). siNOD2 knockdown monocytes were stimulated with 1 g/ml of syn-MDP, mLEP-MDP(NH2), or
mLEP-MDP and induction of IL-32, IL1B, and IL-6 mRNA, shown as fold change (FC) compared to the medium control (B), and protein expression was
measured (C). Data are represented as means SEM (n	 4). Statistical significance was calculated by two-tailed Student’s t test. Asterisks indicate statistically
significant differences compared to the medium control: *, P 0.05; **, P 0.01.
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idence that host pattern receptors of the innate immune system
can recognize naturally occurring structural variants of MDP, in-
cluding the M. leprae MDP.
Investigation of the effect of the structure of theM. lepraeMDP
on innate immune responses was undertaken to understand the
relationship between structure and function of this microbial li-
gand. Our strategy was to measure induction of IL-32 in mono-
cytes, given that the M. leprae peptidoglycan fraction containing
the muropeptides uniquely triggers IL-32. There are several mod-
ifications of the M. leprae MDP structure that could relate to bio-
activity. First, the replacement of L-Ala with Gly in the peptide side
chain of the M. leprae MDP did not alter NOD2 activation. Sec-
ond, the presence or absence of an amide in the D-Glu residue in
combination with Gly did not affect the innate immune response.
Third, we were able to confirm that stereospecific alterations block
NOD2 activity, as D-isoglutamine-to-L-isoglutamine alteration
renders MDP inactive (8). Fourth, the muramic acid of M. leprae
MDP is not N-glycolylated, as this bacterium does not contain a
functional namH gene but appeared to be potent in stimulating
cytokine responses and DC differentiation (34). Previously, study
of the namH mutant of M. tuberculosis suggested that N-glycoly-
lation of muramic acid was required to maximally induce TNF-
and IL-6 in macrophages; however, these particular cytokine re-
sponses required costimulation from LPS or trehalose dimycolate
(15). Alternatively, other substitutions might compensate for the
lack of N-glycolylation (14). We note that the muramic acid of M.
leprae is N-acetylated, unlike other mycobacterial MDPs. In sum-
mary, the unique structure of the M. leprae MDP does not inter-
fere with its ability to activate the innate immunity in vitro. Based
on our studies indicating that live M. leprae induces monocytes to
release IL-32 and to differentiate into CD1bDC, and that NOD2
downstream immune responses, including IL-32, are expressed at
the site of leprosy infection, it is reasonable to speculate that the
unique structure of M. leprae MDP does not significantly alter
immune activation in vivo. In addition to inducing IL-32, M. lep-
raeMDP stimulated monocyte release of IL-1 and IL-6, as well as
of TNF- and IL-12p40 (data not shown), and induced DC dif-
ferentiation.
The ability of the M. leprae MDP to induce proinflammatory
cytokines as well as DC differentiation most likely contributes to
host defense, given that NOD2, IL-32, and CD1 DC are more
frequent in the self-limited T-lep versus progressive L-lep lesions
(3). Consistent with this hypothesis, single-nucleotide polymor-
phisms in the NOD2 gene have implicated this PRR as the key
innate immune receptor that contributes to host defense in lep-
rosy (4, 5). A number of studies have implicated NOD2 directly in
other mycobacterial diseases. In tuberculosis (TB), nonsynony-
mous variants of NOD2 were shown to be associated with active
disease in a cohort of patients from Houston (35). Furthermore,
detection ofM. tuberculosis andM. paratuberculosis in human and
murine macrophages is NOD2 dependent (36, 37), and NOD2 is
important for the cytokine response and NO production in mouse
macrophages infected with M. tuberculosis (38, 39). In a mouse
model of M. tuberculosis infection NOD2 deficiency did not affect
the early phase of infection and bacterial burden (39), but the
pulmonary bacterial burden was increased and survival decreased
in NOD2-deficient mice (38). In addition to leprosy, human vari-
ants of NOD2 have been associated with susceptibility to Crohn’s
disease (4, 5, 40, 41). It is interesting that Crohn’s disease is a
chronic granulomatous disorder of the gut with similarities to
Johnne’s disease, a mycobacterially induced granulomatous dis-
order in cows. However, an association of Crohn’s disease with
mycobacterial infection remains controversial. It should be noted
that despite years of intensive research, the mechanism by which
single-nucleotide polymorphisms (SNPs) in NOD2 lead to the
enhanced inflammation associated with Crohn’s disease remains
enigmatic (4, 5, 42).
It is unclear why M. leprae has evolved to possess a structural
variant of MDP, except to possibly escape immune detection (10).
However, our data indicate that NOD2 recognizes these naturally
occurring structural variants of MDP to mount an effective host
response. Future studies using patient monocytes and/or trans-
fected cell lines are required to determine whether mutations in
NOD2 lead to altered responses against certain structural variants
of MDP, contributing to the pathogenesis of leprosy infection.
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